Literature DB >> 19646862

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

Matti Aapro1, Agustí Barnadas, Robert C Leonard, Maurizio Marangolo, Michael Untch, Lidia Ukarma, Hans-Ulrich Burger, Armin Scherhag, Bruno Osterwalder.   

Abstract

UNLABELLED: PURPOSE, PATIENTS AND METHODS: This retrospective analysis of the BRAVE study evaluated the impact of baseline risk factors and antithrombotic therapy on the risk of thrombovascular events (TVEs) in patients receiving epoetin compared to patients not receiving epoetin.
RESULTS: Baseline risk factors have a significant impact on TVE risk under epoetin therapy. More than 2 risk factors increased the risk of TVEs in patients receiving epoetin (hazard ratio [HR] 2.89, confidence interval [CI] 1.04-8.02, p value [p]=0.04). In patients on epoetin without antithrombotic therapy, the risk for TVEs was higher (HR 4.11, CI 1.37-12.4, p=0.01) compared to those who received antithrombotics (HR 1.37, CI 0.59-3.18, p=0.45).
CONCLUSIONS: Our analysis has identified several risk factors which may impact the risk of TVEs under epoetin therapy. These data suggest that antithrombotic therapy may have the potential to reduce the risk of TVEs under epoetin therapy. These findings are hypothesis-generating and need to be confirmed in a prospective, randomised study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646862     DOI: 10.1016/j.ejca.2009.06.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

Review 1.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

2.  Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events.

Authors:  M Aapro; B Osterwalder; A Scherhag; H U Burger
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

Review 3.  Physiology and pharmacology of erythropoietin.

Authors:  Wolfgang Jelkmann
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

Review 4.  Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.

Authors:  M Aapro; W Jelkmann; S N Constantinescu; B Leyland-Jones
Journal:  Br J Cancer       Date:  2012-03-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.